Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
BioConferenceLive
JIB

New Microplate Reader Optimized for Fluorescent and Bioluminescent Assays

By BiotechDaily International staff writers
Posted on 13 Feb 2014
Image: The GloMax Discover, an integrated multimode detection plate-reader system (Photo courtesy of the Promega Corporation).
Image: The GloMax Discover, an integrated multimode detection plate-reader system (Photo courtesy of the Promega Corporation).
Biotech and other life science researchers now have available a new microplate reader system that provides superior sensitivity, performance, and flexibility with minimal user intervention.

Promega Corporation (Madison, WI, USA) has launched the GloMax Discover, an integrated multimode detection plate-reader system. This system was designed to enable investigators to easily study cell signaling and metabolism, while monitoring cell viability, apoptosis, and cytotoxicity, or to study gene expression with a wide variety of reporter assays.

The instrument offers a broad dynamic range for both strong and weak bioluminescence experimental samples, superior luminescence sensitivity, and low well-to-well cross talk, which enables users to generate more usable data from each experiment. The GloMax Discover provides flexible use of filters for fluorescence intensity, BRET (bioluminescence resonance energy transfer), FRET (fluorescence resonance energy transfer), filtered luminescence, and UV-visible absorbance measurements. In addition, the system encourages seamless integration with industry-leading bioluminescent assays.

The GloMax Discover is driven by proprietary software that provides quick and easy navigation through the control options, preloaded assay protocols, and drag-and-drop protocol customization.

Michael Bjerke, global product manager, detection at Promega, said, “Scientific discoveries not only require the right type of assay to achieve the necessary sensitivity, dynamic range, and reproducibility, they require the right type of instrument. Instruments with enhanced optical capability, such as our GloMax systems with high quality luminescence, enable superior assay performance and experimental design.”

Related Links:

Promega Corporation



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Microcomputed tomography images (top) and histology images (bottom) of the knees of mice fed a very high fat diet containing omega-3 fatty acid supplement (left) or only omega-6 fatty acids (right) after a knee injury. The omega-6 diet showed abnormal bone remodeling and calcified tissue formation in the joint (white arrow). The omega-6 diet also showed significant loss of cartilage (red staining, yellow arrowhead) and increased joint inflammation (Photo courtesy of Duke University).

Dietary Omega-3 Fatty Acids Moderate Severity of Osteoarthritis in a Mouse Model

Researchers working with an osteoarthritis (OA) obese mouse model found that the fat content of the animals' diet contributed more to the development or arrest of OA than did body weight.... Read more

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.